ABT-239

ABT-239 is a drug that was developed by Abbott Laboratories. It is a potent and selective antagonist of the histamine H3 receptor, and has nootropic and neuroprotective effects in animal studies. ABT-239 has been researched for potential use in the treatment of Alzheimer's disease and schizophrenia, but development was discontinued due to the risk of QTc prolongation.

Pharmacology[edit | edit source]

ABT-239 is a potent and selective antagonist of the histamine H3 receptor. This receptor is found in the central nervous system and is involved in the regulation of neurotransmitter release. By blocking this receptor, ABT-239 increases the release of acetylcholine and dopamine, neurotransmitters that are involved in cognition and mood.

Clinical trials[edit | edit source]

ABT-239 has been tested in phase I and II clinical trials for the treatment of Alzheimer's disease and schizophrenia. However, development was discontinued due to the risk of QTc prolongation, a condition that can lead to life-threatening arrhythmias.

Potential therapeutic uses[edit | edit source]

Despite the discontinuation of its development, ABT-239 has been the subject of research due to its potential therapeutic uses. Its ability to increase the release of acetylcholine and dopamine makes it a potential treatment for cognitive disorders such as Alzheimer's disease and attention deficit hyperactivity disorder (ADHD). Furthermore, its potential to modulate mood suggests it could be useful in the treatment of depression and anxiety disorders.

See also[edit | edit source]

ABT-239 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.